Volume 12, Issue 2

June 2013
(16) Review, (1) Editorial

Editorial

Editorial
  • Güven Aslan
Bull Urooncol 2013; 12: 0-0

Review

The importance of cellular androgenic hormonal mechanisms in treatment and progression of prostate cancer
  • Bertrand Tombal
Bull Urooncol 2013; 12: 65-70
Is prostate cancer be screened according to Turkey data?
  • Rahmi Gökhan Ekin
  • Ferruh Zorlu
Bull Urooncol 2013; 12: 71-75
Active surveillance in low risk prostate cancer
  • Ozan Bozkurt
  • Ömer Demir
Bull Urooncol 2013; 12: 76-79
Treatment options in low-intermediate risk prostate cancer
  • Saadettin Yılmaz Eskiçorapçı
  • Deniz Bolat
Bull Urooncol 2013; 12: 80-85
Radiotherapy in low and intermediate-risk prostate cancer
  • Deniz Yalman
Bull Urooncol 2013; 12: 86-91
Robot-assisted radical prostatectomy: Operative technique — step by step
  • Bora Özveren
  • Levent Türkeri
Bull Urooncol 2013; 12: 92-96
Surgical treatment and/or radiotherapy in high risk prostate cancer
  • Fatih Bıçaklıoğlu
  • Cenk Acar
  • Sinan Sözen
Bull Urooncol 2013; 12: 97-101
Androgene suppression therapy in addition to radical radiotherapy in high risk prostate carcinoma
  • İlknur Bilkay Görken
Bull Urooncol 2013; 12: 102-105
New treatment options for the castration resistant prostate cancer targeting the androgen synthesis and androgen receptor
  • Yavuz Selim Süral
  • Çağ Çal
Bull Urooncol 2013; 12: 106-110
New treatment options in castration resistant prostate cancer: enzalutamide and abiraterone acetate
  • Bülent Akdoğan
Bull Urooncol 2013; 12: 111-114
New treatment options for the castration resistant prostate cancer: Cabazitaxel and Spileucel-T
  • Gürbüz Görümlü
  • Erdem Göker
Bull Urooncol 2013; 12: 115-117
New treatment options in castration resistant prostate cancer: denosumab, alpharadin
  • Hakan Gemalmaz
Bull Urooncol 2013; 12: 118-122
Relationship between active surveillance / watchfull waiting and quality of life in localised prostate cancer
  • İlker Çelen
  • Yasin Ceylan
Bull Urooncol 2013; 12: 123-126
How shoud PSA repalse (rising PSA) be managed after radical prostatectomy? How should treatment algorithms be shaped?
  • İlker Çelen
  • Murat Lekili
Bull Urooncol 2013; 12: 127-131
Radical prostatectomy indications and outcomes in the high-risk localised prostate cancer
  • Hayrettin Şahin
  • Hasan Deliktaş
Bull Urooncol 2013; 12: 132-136
Salvage radical prostatectomy for locally recurrent prostate cancer following primary radiotherapy
  • Ali Cansu Bozacı
  • Sertaç Yazıcı
Bull Urooncol 2013; 12: 137-141